Opioids And Psychic Pain: Alkermes Uses High-Profile Stage To Highlight Depression Drug
Executive Summary
Biopharma companies working on non-addictive pain drugs and new therapies to treat addiction had a high-profile platform during the most recent meeting of the President’s Commission on opioid abuse. Alkermes made the most of the opportunity.
You may also be interested in...
On Track To Approval, Alkermes Hopes ALKS-5461 Can Change Future Of Depression Therapy
The novel opioid-system antidepressant is being positioned for adjunctive therapy on top of SSRIs, but Alkermes is eyeing other indications, and better ways to stratify and treat depressed patients.
If Alkermes Antidepressant Can Get Past FDA, The Market Might Be There
Alkermes’s announcement of positive findings in the FORWARD-5 trial of its treatment-resistant depression drug ALKS 5461 came as a surprise, given the past two Phase III trials disappointed, but if it can gain approval, the buprenorphine/samidorphan product could meet an unmet need.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.